J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

While AkzoNobel is one of the most diversified paint and coatings producers, it has somewhat focused its portfolio in recent years, exemplified by the sale of its specialty chemical business.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

This Fool considers how two low-risk and well-established FTSE shares could offer stability and growth during a period of market volatility.

Natural product synthesis aims to prepare a complex target molecule such that the product is analytically identical to the naturally occurring compound, termed a natural product. It is used for ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Top investment firms expect non-US stocks to outperform. Here are Morningstar’s top international stock and ETF picks today.

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting ...